Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | HTR3A | P46098 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23411442 | 0.87 | MAPT (0.49) | LMNAPOLBMAPTTHRBSMN1; SMN2 | |
| SCHEMBL23411589 | 0.80 | BCHE (0.36) | LMNAPOLBTHRBHTR3AKCNH2 | |
| SCHEMBL23442737 | 0.78 | LMNA (0.55) | LMNAPOLBMAPTHTR2BTHRB | |
| SCHEMBL25174776 | 0.77 | LMNA (0.47) | LMNAPOLBMAPTHTR2BTHRB | |
| SCHEMBL25167085 | 0.77 | LMNA (0.47) | LMNAPOLBMAPTHTR2BTHRB | |
| SCHEMBL23411092 | 0.75 | KDM4E (0.36) | LMNAPOLBMAPTHTR3AKCNH2 | |
| SCHEMBL29890496 | 0.75 | KDM4E (0.36) | LMNAPOLBMAPTHTR3AKCNH2 | |
| SCHEMBL29890355 | 0.72 | HTR4 (0.34) | LMNAPOLBUSP2HTR3AKCNH2 | |
| SCHEMBL4305393 | 0.71 | LMNA (0.53) | LMNAPOLBMAPTHTR2BTHRB | |
| SCHEMBL4305254 | 0.69 | SMN1; SMN2 (0.51) | LMNAMAPTHTR2BTHRBUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | LMNA 1953/4885POLB 1818/4885MAPT 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.